Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5548.

https://doi.org/10.1182/blood-2019-122395

Published: 2019

Journal Articles

Real-World Utilization and Safety of Daratumumab Rapid Infusion Administered in a Community Setting: A Retrospective Observational Study

Lucio Gordon, MD, Melody Chang, RPh, MBA, Marie-Hélène Lafeuille, MA, Hela Romdhani, PhD, Faud Paramasivam, Xinmei Zhu, PhD, Sriya Gunawardena, Eric M Maiese, PhD

Blood (2019) 134 (Supplement_1): 5575.

https://doi.org/10.1182/blood-2019-128515

Published: 2019

Journal Articles

Antibody-Associated Autoimmune Disease (AAD) in Children with Cancer in Immune Recovery Phase Following Cessation of Chemotherapy

Akihiro Iguchi, MD PhD, Kazuya Hara, MD, Yukayo Terashita, MD, Minako Sugiyama, MD, Yuko Cho, MD, Atsushi Manabe, MD PhD

Blood (2019) 134 (Supplement_1): 1052.

https://doi.org/10.1182/blood-2019-123015

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

Hanna A. Knaus, MD, Hubert Hackl, Amanda Blackford, Sofia Berglund, Raul Montiel-Esparza, Joshua F Zeidner, MD, Ivana Gojo, MD, Leo Luznik, MD

Blood (2019) 134 (Supplement_1): 2711.

https://doi.org/10.1182/blood-2019-128742

Published: 2019

Journal Articles

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Blood (2019) 134 (Supplement_1): 877.

https://doi.org/10.1182/blood-2019-131255

Published: 2019

Journal Articles

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Micah Denay McCumber, BS, MS, Aaron Mark Wendelboe, PhD MS, Janis Campbell, PhD GISP, Kai Ding, PhD, Michele G Beckman, MPH, Nimia L Reyes, MD MPH, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3463.

https://doi.org/10.1182/blood-2019-130604

Published: 2019

Journal Articles

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Aurélie Cabannes, MD, Aline Schmidt, MD, Eolia Brissot, MD PhD, Marie Balsat, MD, Sébastien Maury, MD PhD, Francoise Isnard, MD PhD, Patrice Chevallier, MD, Victoria Cacheux, Thomas Cluzeau, MD PhD, Carlos Graux, Ludovic Lhermitte, MD PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Vahid Asnafi, MD PhD, Philippe Rousselot, MD PhD

Blood (2019) 134 (Supplement_1): 1339.

https://doi.org/10.1182/blood-2019-130818

Published: 2019

Journal Articles

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Blood (2019) 134 (Supplement_1): 1416.

https://doi.org/10.1182/blood-2019-127082

Published: 2019

Journal Articles

Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study

Blood (2019) 134 (Supplement_1): 1423.

https://doi.org/10.1182/blood-2019-122468

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

Blood (2019) 134 (Supplement_1): 2700.

https://doi.org/10.1182/blood-2019-127475

Published: 2019

Journal Articles

A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-Cells

Irene Cortese, Austin John Barrett, David F. Stroncek, Steven Highfill, PhD, Erin Beck, Frances Andrada, Joan Ohayon, Jennifer Dwyer, Matthew Schindler, Georg Aue, Daniel Reich, Avindra Nath, Pawel Muranski, MD

Blood (2018) 132 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2018-99-119832

Published: 2018

Journal Articles

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, MD, Paula Rodriguez Otero, MD, Sara Bringhen, MD, Stefania Oliva, Axel Nogai, MD, Michel Attal, MD PhD, Philippe Moreau, Dheepak Kanagavel, Thomas F Fitzmaurice, PhD, Junlong Wu, Joaquin Martinez Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 595.

https://doi.org/10.1182/blood-2018-99-111244

Published: 2018

Journal Articles

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Frederic Picou, PhD, Jean-Claude Chomel, PharmD PhD, Marie Christine Bene, PharmD, Marc G. Berger, MD PhD, Thierry Fest, Valerie Ugo, MD PhD, Eric Lippert, MD PhD, Marion Socco-Luca, Martine Delain, MD, Marie-Helene Estienne, PharmD, Olivier Herault, MD PhD

Blood (2018) 132 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2018-99-118297

Published: 2018

Journal Articles

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Francesco Manfredi, MD, Maddalena Noviello, PhD, Eliana Ruggiero, PhD, Tommaso Perini, MD, Giacomo Oliveira, PhD, Filippo Cortesi, PhD, Pantaleo De Simone, MD, Cristina Toffalori, Valentina Gambacorta, MSc, Raffaella Greco, MD, Jacopo Peccatori, Monica Casucci, PhD, Giulia Casorati, PhD, Paolo Dellabona, MD PhD, Nicoletta Cieri, MD PhD, Attilio Bondanza, MD, Luca Vago, MD PhD, Fabio Ciceri, MD, Chiara Bonini, MD

Blood (2018) 132 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2018-99-118104

Published: 2018

NARROW

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Real-World Utilization and Safety of Daratumumab Rapid Infusion Administered in a Community Setting: A Retrospective Observational Study

Antibody-Associated Autoimmune Disease (AAD) in Children with Cancer in Immune Recovery Phase Following Cessation of Chemotherapy

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Integrating ELN Criteria and a 'Knowledge Bank' Approach to Guide Allogeneic Stem Cell Transplantation (SCT) Indication in Younger Adults with Acute Myeloid Leukemia (AML): An Acute Leukemia French Association Study

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC)

A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-Cells

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Prediction of One-Year Molecular Response to Imatinib at Diagnosis of Chronic Myeloid Leukemia By Scoring Gene Expression Levels of Antioxidant Enzymes

Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only